HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

SARS-CoV-2 Neutralizing Antibodies Fade Quickly in Recovering COVID-19 Patients After Symptoms Subside

By HospiMedica International staff writers
Posted on 19 Oct 2020
Print article
Illustration
Illustration
SARS-CoV-2 antibody levels in the blood of COVID-19 patients decline rapidly during the weeks after their bodies have cleared the virus and symptoms have subsided, according to a new study.

Researchers at the University of Montreal (Montreal, QC, Canada) are attempting to understand how the levels of antibodies change over time in order to optimize the use of blood plasma from recovering patients for treating those with severe COVID symptoms. Their research is also critical for understanding the efficacy of COVID-19 vaccines and finding out whether previously infected people face a risk of re-infection. Previous studies have revealed that antibodies against the SARS-CoV-2 spike protein peak two or three weeks following the onset of symptoms. In an earlier study of more than 100 patients by researchers at the University of Montreal, it was found that plasma’s ability to neutralize the SARS-CoV-2 virus declined significantly between three and six weeks after the onset of symptoms.

In the new longitudinal study, the team analyzed blood samples collected at one-month intervals from 31 individuals who were recovering from COVID-19. The researchers measured the levels of immunoglobulins that act against the coronavirus S protein and tested the ability of the antibodies to neutralize SARS-CoV-2. They found that the levels of Immunoglobulins G, A, and M that target the binding site declined between six and 10 weeks after the onset of symptoms and the ability of the antibodies to neutralize the virus also reduced over the same period.

Small studies have found that convalescent plasma can reduce the severity of illness and reduce hospitalization in COVID-19 patients, but it is yet to demonstrate benefits in randomized trials. Recovering patients cannot donate blood until at least 14 days after symptoms have subsided in order to allow their body to clear the viral particles, although the researchers have concluded that convalescent plasma must be collected during a specific window of time after recovery for deriving any clear benefits.

“We don’t want to transfuse the virus, just transfuse the antibodies,” said Andrés Finzi, Ph.D., at the University of Montreal. “But at the same time, our work shows that the capacity of the plasma to neutralize viral particles is going down during those first weeks.”

Related Links:
University of Montreal

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Autoclavable Camera System
Precision AC

Print article

Channels

Critical Care

view channel
Image: The new risk assessment tool determines patient-specific risks of developing unfavorable outcomes with heart failure (Photo courtesy of 123RF)

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

Heart failure is a serious condition where the heart cannot pump sufficient blood to meet the body's needs, leading to symptoms like fatigue, weakness, and swelling in the legs and feet, and it can ultimately... Read more

Surgical Techniques

view channel
Image: The multi-sensing device can be implanted into blood vessels to help physicians deliver timely treatment (Photo courtesy of IIT)

Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health

Researchers have embarked on a project to develop a multi-sensing device that can be implanted into blood vessels like peripheral veins or arteries to monitor a range of bodily parameters and overall health status.... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more